PURPOSE: Colon cancer is a major cause of cancer deaths. Dietary factors contribute substantially to the risk of this malignancy. Western-style diets promote development of azoxymethane-induced colon cancer. Although we showed that epidermal growth factor receptors (EGFR) controlled azoxymethane tumorigenesis in standard fat conditions, the role of EGFR in tumor promotion by high dietary fat has not been examined. EXPERIMENTAL DESIGN: A/J x C57BL6/J mice with wild-type Egfr (Egfr(wt)) or loss-of-function waved-2 Egfr (Egfr(wa2)) received azoxymethane followed by standard (5% fat) or western-style (20% fat) diet. As F(1) mice were resistant to azoxymethane, we treated mice with azoxymethane followed by one cycle of inflammation-inducing dextran sulfate sodium to induce tumorigenesis. Mice were sacrificed 12 weeks after dextran sulfate sodium. Tumors were graded for histology and assessed for EGFR ligands and proto-oncogenes by immunostaining, Western blotting, and real-time PCR. RESULTS: Egfr(wt) mice gained significantly more weight and had exaggerated insulin resistance compared with Egfr(wa2) mice on high-fat diet. Dietary fat promoted tumor incidence (71.2% versus 36.7%; P < 0.05) and cancer incidence (43.9% versus 16.7%; P < 0.05) only in Egfr(wt) mice. The lipid-rich diet also significantly increased tumor and cancer multiplicity only in Egfr(wt) mice. In tumors, dietary fat and Egfr(wt) upregulated transforming growth factor-alpha, amphiregulin, CTNNB1, MYC, and CCND1, whereas PTGS2 was only increased in Egfr(wt) mice and further upregulated by dietary fat. Notably, dietary fat increased transforming growth factor-alpha in normal colon. CONCLUSIONS: EGFR is required for dietary fat-induced weight gain and tumor promotion. EGFR-dependent increases in receptor ligands and PTGS2 likely drive diet-related tumor promotion.
PURPOSE:Colon cancer is a major cause of cancer deaths. Dietary factors contribute substantially to the risk of this malignancy. Western-style diets promote development of azoxymethane-induced colon cancer. Although we showed that epidermal growth factor receptors (EGFR) controlled azoxymethane tumorigenesis in standard fat conditions, the role of EGFR in tumor promotion by high dietary fat has not been examined. EXPERIMENTAL DESIGN: A/J x C57BL6/J mice with wild-type Egfr (Egfr(wt)) or loss-of-function waved-2Egfr (Egfr(wa2)) received azoxymethane followed by standard (5% fat) or western-style (20% fat) diet. As F(1) mice were resistant to azoxymethane, we treated mice with azoxymethane followed by one cycle of inflammation-inducing dextran sulfate sodium to induce tumorigenesis. Mice were sacrificed 12 weeks after dextran sulfate sodium. Tumors were graded for histology and assessed for EGFR ligands and proto-oncogenes by immunostaining, Western blotting, and real-time PCR. RESULTS:Egfr(wt) mice gained significantly more weight and had exaggerated insulin resistance compared with Egfr(wa2)mice on high-fat diet. Dietary fat promoted tumor incidence (71.2% versus 36.7%; P < 0.05) and cancer incidence (43.9% versus 16.7%; P < 0.05) only in Egfr(wt) mice. The lipid-rich diet also significantly increased tumor and cancer multiplicity only in Egfr(wt) mice. In tumors, dietary fat and Egfr(wt) upregulated transforming growth factor-alpha, amphiregulin, CTNNB1, MYC, and CCND1, whereas PTGS2 was only increased in Egfr(wt) mice and further upregulated by dietary fat. Notably, dietary fat increased transforming growth factor-alpha in normal colon. CONCLUSIONS:EGFR is required for dietary fat-induced weight gain and tumor promotion. EGFR-dependent increases in receptor ligands and PTGS2 likely drive diet-related tumor promotion.
Authors: Gregory P Boivin; Kay Washington; Kan Yang; Jerrold M Ward; Theresa P Pretlow; Robert Russell; David G Besselsen; Virginia L Godfrey; Tom Doetschman; William F Dove; Henry C Pitot; Richard B Halberg; Steven H Itzkowitz; Joanna Groden; Robert J Coffey Journal: Gastroenterology Date: 2003-03 Impact factor: 22.682
Authors: J L Reiter; D W Threadgill; G D Eley; K E Strunk; A J Danielsen; C S Sinclair; R S Pearsall; P J Green; D Yee; A L Lampland; S Balasubramaniam; T D Crossley; T R Magnuson; C D James; N J Maihle Journal: Genomics Date: 2001-01-01 Impact factor: 5.736
Authors: Reade B Roberts; Lu Min; M Kay Washington; Sandra J Olsen; Stephen H Settle; Robert J Coffey; David W Threadgill Journal: Proc Natl Acad Sci U S A Date: 2002-01-29 Impact factor: 11.205
Authors: Philip E Dubé; Fang Yan; Shivesh Punit; Nandini Girish; Steven J McElroy; M Kay Washington; D Brent Polk Journal: J Clin Invest Date: 2012-07-09 Impact factor: 14.808
Authors: Hongyan Zhu; Urszula Dougherty; Victoria Robinson; Reba Mustafi; Joel Pekow; Sonia Kupfer; Yan Chun Li; John Hart; Kathleen Goss; Alessandro Fichera; Loren Joseph; Marc Bissonnette Journal: Mol Cancer Res Date: 2011-06-08 Impact factor: 5.852
Authors: Urszula Dougherty; Reba Mustafi; Haider I Haider; Abdurahman Khalil; Jeffrey S Souris; Loren Joseph; John Hart; Vani J Konda; Wei Zhang; Joel Pekow; Yan Chun Li; Marc Bissonnette Journal: Cancer Prev Res (Phila) Date: 2019-05-14
Authors: Urszula Dougherty; Reba Mustafi; Farhana Sadiq; Anas Almoghrabi; Devkumar Mustafi; Maggi Kreisheh; Sumana Sundaramurthy; Weicheng Liu; Vani J Konda; Joel Pekow; Sharad Khare; John Hart; Loren Joseph; Alice Wyrwicz; Gregory S Karczmar; Yan Chun Li; Marc Bissonnette Journal: Clin Cancer Res Date: 2014-09-11 Impact factor: 12.531